Two posters presented at the 2023 Fall Clinical Dermatology Conference assessed phase 4 study findings on tildrakizumab in patients with moderate to severe plaque psoriasis.

Related Keywords

, Clinical Dermatology Conference , Work Productivity , Activity Impairment Questionnaire , Psoriasis , Tildrakizumab , Safety And Efficacy , Psoriasis Treatments , Plaque Psoriasis ,